Now Approved!
VOCERYQ is the nonsurgical treatment indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP).1
This indication is approved under accelerated approval based on the reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies.
Prior to initial administration of VOCERYQ, perform a surgical debulking of visible papilloma to establish minimal residual disease; no planned surgical intervention is required as part of the 9-week dosing regimen.1
Sign up for info and updates
Get the latest information about VOCERYQ, a new nonsurgical treatment for adults with RRP that uses DNA technology, or call 1-855-INOVIO1 to speak with a representative today.
Indication
VOCERYQ is indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP).
This indication is approved under accelerated approval based on the reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies.
Important Safety Information
- Injection-site reactions have occurred with VOCERYQ. Monitor patients for local site reactions for at least 30 minutes after treatment and manage accordingly
- Electroporation-related adverse reactions may occur with VOCERYQ administration and may include brief muscle contractions or tetany, temporary bleeding at the administration site, anxiety, vasovagal reactions including lightheadedness and dizziness, and transient changes in creatine phosphokinase. Injection-site erythema and injection-site pain are also associated with the electroporation procedure
- During administration, avoid injections on or within sites with a cardioverter-defibrillator or pacemaker on the ipsilateral side; metal implants or implantable medical devices within the injection site; or skin that is irritated, damaged or has bruises, scars, or tattoos at the intended administration site. Do not administer to patients with any medical condition, laboratory abnormality, or clinical circumstance that may increase the risk of treatment-related complications
The most common adverse reactions (≥5%) included injection-site reactions, headache, fatigue, hypertension, nausea, and dizziness.
Please see full Prescribing Information.
Reference: 1. VOCERYQ Prescribing Information. INOVIO Pharmaceuticals, Inc., 2026.